HEALTH RESPONSE

www.healthresponse.ca
Canada's National Pharmacy NewsLine
Pricing | New Products | Formulary News | DIN Changes | Packaging Company News

Pharmacy BULLETIN BOARD

Retail Issue ■ Monday June 8, 2015

Odan Laboratories is pleased to introduce their new sodium chloride product:

ODAN-SODIUM CHLORIDE
OPHTHALMIC OINTMENT USP

Odan-Sodium Chloride™ ophthalmic ointment is indicated for the temporary relief of corneal edema

The only equivalent to Muro-128†

Product	Format	Odan	K & F	McKesson
Odan-Sodium Chloride *Ointment* NPN 80046696	3.5 g	12735	149285	067490
Odan-Sodium Chloride *Solution** NPN 80046737	15 mL	12515	149153	067456

*Covered by the British-Columbia formulary

To order, please contact your wholesaler or contact Odan directly by phone at 1-800-387-9342 or by e-mail at info@odanlab.com.

100% CANADIAN COMPANY • 100% CANADIEN

ODAN
www.odanlab.com

*Odan Laboratories Ltd., Montreal, QC, Canada H9R 2Y6
†Muro 128 is a registered trademark of Bausch & Lomb

TARO

Lower Cost Generic Alternative to Imitrex® Injection[1]

PrTaro-Sumatriptan

Sumatriptan Succinate Injection 6 mg/0.5 mL

- Generic Version of Imitrex® Injection[1]
- High Quality, Lower Price Alternative
- One piece disposable device with no assembly required
- Indicated for the acute treatment of migraine attacks with or without aura[2]

Subcutaneous Injection 6 mg/0.5 mL

DIN	Size	UPC	Wholesaler			
			Mckesson	K&F	Procurity	McMahon
02361698	2 x 0.5 mL	063691068056	010333	119700	251763	10056869

For further information, or to place an order for **Taro-Sumatriptan** Injection, please contact your Taro Representative, your wholesaler, our Customer Service department at **1-800-268-1975**, or visit our Website at **www.taro.ca**.

[1]Data on file, Taro Pharmaceuticals Inc.
[2]Taro-Sumatriptan Product Monograph
®Imitrex is a registered trademark, used under license of GlaxoSmithKline Inc.
Taro is a registered trademark of Taro Pharmaceuticals Inc.

■ FROM THE NEWSWIRE ■

MONTREAL: A new Bristol-Myers Squibb immunotherapy, Opdivo™ (nivolumab), is the first PD-1 inhibitor to demonstrate superior overall survival versus standard of care (docetaxel) in previously-treated patients with advanced, non-squamous non-small cell lung cancer (NSCLC). Results from the open-label, randomized Phase 3 study were presented at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago.

HOPKINTON, Mass.: For years, the radiology industry has focused on reducing, or eliminating patient exposure to radiation. Recently, the industry has shifted attention to the cumulative effect radiation exposure has over the course of a physician's career. To address this, Unfors RaySafe, a Fluke Biomedical Company, launched LowerMyDose.com to enable physicians and clinical staff to educate themselves on the risks of radiation exposure and measures that can be taken to protect themselves. This first-of-its kind community delivers the most current research about radiation exposure, as well as stories and anecdotes from practicing clinical personnel. LowerMyDose.com promotes peer-to-peer engagement through real-life experience sharing about the concerns of excessive and unnecessary radiation exposure.

MONTREAL: Bristol-Myers Squibb and AbbVie announced that the addition of investigational immunotherapy, elotuzumab, to standard treatment for multiple myeloma, a blood cancer, showed significant reduction in the risk of disease progression and a higher two-year progression-free survival (PFS) rate. These study results were presented at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago and simultaneously published in the New England Journal of Medicine.

TORONTO: Data from the Phase 3 CLL3001 (HELIOS) trial demonstrated that the combination of ibrutinib (IMBRUVICA®) plus bendamustine and rituximab (BR) reduced the risk of progression or death by 80 per cent and also significantly improved overall response rate (ORR) versus placebo plus BR in patients with relapsed or refractory (R/R) chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL). Janssen Research & Development, LLC (Janssen) announced these data at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL and were presented by the lead author of the study, Dr. Asher Chanan-Khan. IMBRUVICA® is jointly developed and commercialized by Janssen Biotech, Inc. and Pharmacyclics LLC.

MISSISSAUGA, ON: Biogen Canada has announced that Quebec's Institut national d'excellence en santé et services sociaux (INESSS) has updated its recommendation for TECFIDERA™ (dimethyl fumarate) 120 mg and 240 mg to be included on the provincial drug formulary under "Médicament d'exception" as first-line oral treatment for adults with relapsing-remitting multiple sclerosis (RRMS). TECFIDERA™ is indicated as monotherapy for the treatment of RRMS to reduce the frequency of clinical exacerbations and to delay the progression of disability.

Copyright © 2015 Health Response of Canada. All rights reserved.